Xiaolin Liu is a prominent inventor based in Jiangsu, China, known for his significant contributions to the field of biotechnology. With a total of 8 patents to his name, Liu has made remarkable advancements in the development of therapeutic antibodies.

Latest Patents

Among his latest patents is the "Anti-LAG-3 antibody and use thereof," which pertains to a novel antibody and its fragments that specifically bind to LAG-3. This invention includes a composition comprising the antibody or its fragment, as well as a nucleic acid encoding the antibody. The therapeutic and diagnostic applications of this invention are noteworthy, particularly in combination therapies with other agents like anti-PD-1 or anti-PD-L1 antibodies. Another significant patent is the "Anti-OX40 antibody and use thereof," which involves an antibody and its fragment that specifically binds to OX40. This patent also covers a nucleic acid encoding the antibody and its related uses in treatment and diagnosis.

Career Highlights

Xiaolin Liu has worked with Innovent Biologics (Suzhou) Co., Ltd. and Innovent Biologics Co., Ltd., where he has played a crucial role in advancing biopharmaceutical innovations. His work has contributed to the development of new therapeutic options in the field of immunology.

Collaborations

Liu has collaborated with notable colleagues such as Andy Tsun and Cheng Chen, enhancing the collaborative efforts in research and development within his field.

Conclusion

Xiaolin Liu's innovative work in antibody development and his contributions to biotechnology underscore his importance as an inventor. His patents reflect a commitment to advancing medical science and improving therapeutic strategies.

This text is generated by artificial intelligence and may not be accurate.